DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

Downloadable slideset from S. Vincent Rajkumar, MD and Thomas G. Martin, MD, on considerations for treatment of multiple myeloma at first relapse, provided by Clinical Care Options (CCO)

Thomas G. Martin, MD S. Vincent Rajkumar, MD Released: December 29, 2022

Webcast from a live meeting series presented by Dr Sarah Holstein on advancements in first-line care for newly diagnosed multiple myeloma, from Clinical Care Options (CCO)

Sarah A. Holstein, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Phase I/II trial of mezigdomide + dexamethasone in relapsed/refractory multiple myeloma, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Long-term PFS data exploring duration of lenalidomide maintenance therapy in patients with multiple myeloma after ASCT, presented at ASH 2022 and reported by Clinical Care Options (CCO)